Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Jun;27(3):391-404.
doi: 10.1016/j.berh.2013.07.008.

Cutaneous lupus erythematosus: diagnosis and treatment

L G Okon  1 , V P Werth
Affiliations
Review

Cutaneous lupus erythematosus: diagnosis and treatment

L G Okon et al. Best Pract Res Clin Rheumatol. 2013 Jun.

Abstract

Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus. The diagnosis of these diseases requires proper classification of the sub-type, through a combination of physical examination, laboratory studies, histology, antibody serology and occasionally direct immunofluorescence, while ensuring to exclude systemic disease. The treatment of cutaneous lupus consists of patient education on proper sun protection along with appropriate topical and systemic agents. Systemic agents are indicated in cases of widespread, scarring or treatment-refractory disease. In this chapter, we discuss issues in classification and diagnosis of the various sub-types of CLE, as well as provide an update on therapeutic management.

Keywords: Acute cutaneous lupus erythematosus; Chronic cutaneous lupus erythematosus; Cutaneous lupus erythematosus; Diagnosis; Discoid lupus erythematosus; Lupus erythematosus profundus; Lupus erythematosus tumidus; Sub-acute cutaneous lupus erythematosus; Systemic lupus erythematosus; Treatment.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Algorithm for cutaneous lupus erythematosus treatment. Localized disease is initially treated with topical agents (either corticosteroids (CS) or calcineurin inhibitors (CI)). Hydroxychloroquine (HCQ) is also often used, depending on the site or if there is scarring disease. Widespread or scarring disease treatment starts with topicals and HCQ. If this fails, quinacrine is added to HCQ. If this regimen fails, a switch to chloroquine (CQ) can be made, while continuing quinacrine. If this fails, other options include mycophenolate mofetil (MM) or mycophenolate sodium (MS), azathioprine, dapsone, retinoids and thalidomide can be considered. In the case of failure of these agents, experimental therapy can be considered.
See this image and copyright information in PMC

References

    1. Tebbe B, Orphanos CE. Epidemiology and socioeconomic impact of skin disease in lupus erythematosus. Lupus. 1997;6:96–104. - PubMed
    1. Biazar C, Sigges J, Nikolaos P, et al. Cutaneous lupus erythematosus: First multicenter database analysis of 1002 patients from the European Society of Cutaneous Lupus Erythematosus (EUSCLE) Autoimmunity Rev. 2013;12:444–454. - PubMed
    1. Albrecht J, Berlin JA, Braverman IM, et al. Dermatology position paper on the revision of the 1982 ACR criteria for systemic lupus erythematosus. Lupus. 2004;(13):839–849. - PubMed
    1. Gronhagen CM, Fored CM, Granath F, Nyberg F. Cutaneous lupus erythematosus and the association with systemic lupus erythematosus: a population-based cohort of 1088 patients in Sweden. Br J Dermatol. 2011;164(6):1335–41. - PubMed
    1. Wieczorek IT, Propert K, Okawa J, Werth VP. Progression from cutaneous to systemic lupus erythematosus by ACR criteria usually occurs with mild disease and few systemic symptoms. J Invest Dermatol (Abstract) 2012;132:S45.

MeSH terms

Substances